News and Trends 19 May 2023 Researchers make cancer weight loss pathway discovery Nearly half of all cancer patients suffer from excessive weight loss due to the loss of adipose and skeletal muscle tissues, or cachexia. This progressive illness not only reduces quality of life for cancer patients but also poses a serious threat for treatment since it obstructs the use of effective medicines, especially in advanced stages. […] May 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Google Cloud adds AI solutions for drug discovery Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and […] May 19, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Could a salt flats pigment treat cancer? Researchers have identified the anti-cancer capacity of a pigment present in the Santa Pola salt flats in eastern Spain. The pigment is produced by certain microorganisms, the ‘halophilic archaea’, in order to protect themselves from the sun, and its anti-tumor capacity has been tested in several types of breast cancer. The study took place at […] May 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Industry responds to UK science strategy launch The UK Health Security Agency’s (UKHSA) has launched a 10-year science strategy, setting out how science can save more lives and contribute to the U.K.’s ambition of being a global science superpower. The strategy sets out how the UKHSA scientific capabilities – including genomics, vaccine evaluation, surveillance, data science, diagnostics and toxicology – will be […] May 18, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 8 rare diseases selected for gene therapy trial portfolio The Foundation for the National Institutes of Health (FNIH) says the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio. This portfolio pioneers a novel approach to gene therapy development for rare diseases by demonstrating that manufacturing and testing standards can provide a streamlined approval […] May 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 New epilepsy study could lead to new treatment options The mechanisms underlying the pathogenesis of epilepsy, a neurological disorder characterized by excessive electrical activity in the brain, remain unknown. Now, using a novel radiotracer, researchers from Japan have been able to offer insight into the role of AMPAR trafficking in epileptogenesis. The radio tracer is [11C]K-2, the first technology to visualize and quantify α-amino-3-hydroxy-5-methyl-4-isoxazole […] May 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Sania Therapeutics launches to advance neural circuit dysfunction medicines Sania Therapeutics, which develops genetic medicines for neural circuit dysfunction, has launched with the unveiling of its platforms at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania Therapeutics’ approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, and tuneable conditionally-activated ion channels. […] May 18, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Diagnosing inflammatory diseases with synthetic peptides Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases Scribe Therapeutics Inc., a company creating genetic medicines through its CRISPR by Design approach to genetic modification, has announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The deal gives Prevail exclusive rights to Scribe Therapeutics’ CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 Molsid developing rapid AMR test Start-up biomed Molsid is developing the first rapid test to detect the potential presence of antimicrobial resistance (AMR) directly in primary clinical samples. ORSET Group and PULSALYS, the SATT in Lyon, extended financing to the company in March 2023. This was followed by the signing of an i-DEMO contract with the French investment bank bpiFrance. […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis SiSaf Ltd, an RNA delivery and therapeutics company, has announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA. Also, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted rare pediatric disease designation […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email